United Therapeutics Corp. (NASDAQ:UTHR) has earned an average rating of “Hold” from the twelve ratings firms that are covering the stock. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $146.88.

UTHR has been the topic of a number of research analyst reports. Zacks Investment Research upgraded United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 price target on the stock in a research note on Tuesday, July 26th. Cowen and Company restated a “buy” rating and set a $144.00 price target on shares of United Therapeutics Corp. in a research note on Friday, September 23rd. Ladenburg Thalmann raised United Therapeutics Corp. from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $128.00 to $138.00 in a report on Friday, October 28th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 target price on shares of United Therapeutics Corp. in a report on Friday, July 29th. Finally, HC Wainwright reaffirmed a “hold” rating on shares of United Therapeutics Corp. in a report on Friday, July 29th.

In related news, CEO Martine A. Rothblatt sold 1,232 shares of the business’s stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $132.94, for a total transaction of $163,782.08. Following the completion of the sale, the chief executive officer now directly owns 1,372 shares in the company, valued at $182,393.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Patusky sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $122.73, for a total value of $613,650.00. Following the sale, the director now owns 5,000 shares of the company’s stock, valued at $613,650. The disclosure for this sale can be found here. 7.50% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of UTHR. Daiwa Securities Group Inc. boosted its stake in shares of United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 150 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 190 shares during the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of United Therapeutics Corp. during the third quarter valued at approximately $201,000. BancorpSouth Inc purchased a new stake in shares of United Therapeutics Corp. during the third quarter valued at approximately $224,000. Finally, Zweig DiMenna Associates LLC purchased a new stake in shares of United Therapeutics Corp. during the third quarter valued at approximately $224,000.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 130.94 on Monday. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of 8.86 and a beta of 1.39. United Therapeutics Corp. has a 12-month low of $97.52 and a 12-month high of $164.04. The company has a 50-day moving average of $120.70 and a 200 day moving average of $117.41.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, October 27th. The biotechnology company reported $4.36 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.38 by $0.98. United Therapeutics Corp. had a return on equity of 41.78% and a net margin of 44.40%. The business had revenue of $408.20 million for the quarter, compared to analyst estimates of $400.58 million. During the same quarter in the previous year, the firm earned $3.55 earnings per share. The company’s revenue was up 5.7% on a year-over-year basis. Analysts predict that United Therapeutics Corp. will post $16.29 earnings per share for the current year.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.